SymlinPen Offers Convenient SYMLIN Administration for Enhanced Glucose
Control With Potential Weight Loss
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) announced today the availability of the SymlinPen(TM)
120 and the SymlinPen(TM) 60 pen-injector devices for administering
SYMLIN(R) (pramlintide acetate) injection. These new pre-filled
pen-injector devices feature simple, fixed dosing to improve mealtime
glucose control.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080107/LAM117)
"SYMLIN offers enhanced blood glucose control with potential weight
loss for patients with diabetes using mealtime insulin, enabling them to do
more to manage their diabetes," said Daniel M. Bradbury, President and CEO,
Amylin Pharmaceuticals. "The convenience of the new SymlinPen(TM) with
simple, fixed dosing will make it easier for these patients using multiple
daily injections to start and stay with SYMLIN."
SymlinPen(TM) 120 features fixed dosing to deliver 60 or 120 micrograms
of SYMLIN per dose. SymlinPen(TM) 60 features fixed dosing to deliver 15,
30, 45, or 60 micrograms of SYMLIN per dose. Both pen-injector devices can
be conveniently stored at room temperature not to exceed 86 degrees F (30
degrees C) after first use.
About SYMLIN
SYMLIN is an injectable medicine used to control blood sugar after
meals in adults with type 2 or type 1 diabetes who take mealtime insulin.
SYMLIN is the first and only amylin mimetic for use in patients with
diabetes treated with mealtime insulin. SYMLIN is a synthetic analog of
human amylin, a naturally occurring hormone that is made in the beta cells
of the pancreas, the same cells that make insulin. In patients with type 2
diabetes who use insulin, and in patients with type 1 diabetes, those cells
in the pancreas are either damaged or destroyed, resulting in reduced
secretion of both insulin and amylin after meals. The use of SYMLIN
contributes to glucose control after meals.
Healthcare professionals and people with diabetes may obtain more
information, including the complete Prescribing Information and the
Medication Guide, at http://www.SYMLIN.com.
Important Safety Information
SYMLIN is not intended for all patients with diabetes. SYMLIN is used
with insulin and has been associated with an increased risk of
insulin-induced severe hypoglycemia, particularly in patients with type 1
diabetes. When severe hypoglycemia associated with SYMLIN use occurs, it is
seen within three hours following a SYMLIN injection. If severe
hypoglycemia occurs while operating a motor vehicle, heavy machinery, or
while engaging in other high-risk activities, serious injuries may occur.
Appropriate patient selection, careful patient instruction, and insulin
dose adjustments are critical elements for reducing this risk. This
information is highlighted in a boxed warning in the SYMLIN Prescribing
Information for healthcare
professionals and in a Medication Guide for patients, which will be
distributed by pharmacists.
Other adverse events commonly observed with SYMLIN when co-administered
with insulin were mostly gastrointestinal in nature, including nausea,
which was the most frequently reported. The incidence of nausea was higher
at the beginning of SYMLIN treatment and decreased with time in most
patients. The incidence and severity of nausea are reduced when SYMLIN is
gradually increased to the recommended doses.
About Diabetes
Diabetes is a complex metabolic disease characterized by high blood
glucose levels resulting from a deficiency of both insulin and amylin
secretion. Diabetes represents a large and growing market in the United
States, affecting more than 20 million Americans and growing at three times
the rate of population growth. Approximately 4.2 million patients with
diabetes use insulin. Diabetes is the sixth leading cause of death in the
United States. Poor control of blood glucose may result in severe long-term
complications such as cardiovascular disease, blindness, kidney failure,
nerve damage and amputation.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed
to improving lives through the discovery, development and commercialization
of innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes. Amylin's research and development
activities leverage the company's expertise in metabolism to develop
potential therapies to treat diabetes and obesity. Amylin is located in San
Diego, California with over 1,900 employees nationwide. Further information
on Amylin Pharmaceuticals is available at http://www.amylin.com.
This press release contains forward-looking statements about Amylin,
which involve risks and uncertainties. The Company's actual results could
differ materially from those discussed due to a number of risks and
uncertainties, including risks that SYMLIN and SymlinPen may be affected by
unexpected new data, technical issues, or manufacturing and supply issues;
risks that the results of clinical trials may not be predictive of future
results; and risks inherent in the drug development and commercialization
process. Commercial and government reimbursement and pricing decisions and
the pace of market acceptance may also affect the potential for SYMLIN and
SymlinPen. These and additional risks and uncertainties are described more
fully in the Company's most recently filed SEC documents, including its
Form 10-Q. Amylin undertakes no duty to update these forward-looking
statements.
Alert: Photo advisory coming soon to accompany this release.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20080107/LAM117
AP Archive: http://photoarchive.ap.org AP PhotoExpress
Network: PRN8 PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Alice Bahner Izzo, Executive Director,
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-642-7272
|
